于新芳，医学博士。中南大学肿瘤研究所副所长、中南大学特聘教授、博士生导师、国家级高层次青年人才。先后在克利夫兰医学中心和贝勒医学院从事肿瘤生物学相关研究工作。
近年来，研究方向聚焦于淋巴瘤等恶性肿瘤的发生发展和治疗抵抗机制，阐明了淋巴瘤中关键驱动突变促进肿瘤进展的新机制，发现了新型分子胶化合物，为探索新型淋巴瘤治疗药物提供理论依据。
目前，以第一/通讯作者身份在Blood、J Clin Invest和Cancer Res等期刊发表论文20余篇，引用2500余次。
联系方式 xinfang.yu@csu.edu.cn
教育背景
2009 – 2014 中南大学，病理学与病理生理学，博士，导师：曹亚教授
2005 – 2009 中南大学，药学，学士
科研项目
1. 国家自然科学基金面上项目，PIM1介导弥漫性大B细胞淋巴瘤依鲁替尼耐药的分子机制及干预策略研究，主持。
2. 湖南省青年科学基金A类（原省杰青），MCD型DLBCL发病分子机理和干预策略研究，主持。
代表性论文
1. W. Li#, R. Wang, J. Wang, D. Chai, X. Xie, K. Young, Y. Cao, Y. Li, X. Yu*(独立通讯). Lasalocid-A selectively induces thedegradation of MYD88 in lymphomas harboring theMYD88 L265P mutation. Blood, (2025) 145(10):1047-1060. IF: 21.0, Q1
2. D. Chai, J. Wang, C. Fan, J.M. Lim, X. Wang, P. Neeli, X. Yu, K.H. Young, Y. Li, Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant, Journal of hematology & oncology, 17 (2024) 45. IF: 29.5, Q1
3. Z. Zhou#*, S. Han#, J. Liao#, R. Wang, X. Yu*(并列通讯), M. Li*, Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin, Am J Chin Med, 51 (2023) 2221-2241. IF: 4.8, Q1
4. R. Wang#, Q. Wang#, J. Liao, X. Yu*(并列通讯), W. Li*, Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover, JCI Insight. (2025) 10(6):e186165., IF: 6.3, Q1
5. S. Zhou#,*, D. Chai, X. Wang, P. Neeli, X. Yu, A. Davtyan, K. Young, Y. Li*, AI-powered discovery of a novel p53-Y220C reactivator, Front Oncol, 13 (2023) 1229696. IF: 3.5, Q2
6. X. Yu#* (并列一作/并列通讯), W. Li#, H. Liu, X. Wang, C. Coarfa, C. Cheng, X. Yu, Z. Zeng, Y. Cao, K. Young, Y. Li*, PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination, Journal of clinical investigation, (2023) Feb 1;133(3):e160456. IF: 19.456, Q1
7. X. Yu# (并列一作), L. Zhou#, W. Liu, L. Liu, F. Gao*, W. Li*, H. Liu*, Skp2 stabilizes Mcl-1 and confers
radioresistance in colorectal cancer, Cell death & disease, 13 (2022) 1-13. IF: 9.685, Q1
8. X. Yu(第一作者), W. Li, K.H. Young, Y. Li, Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave, Biomedicines, 9 (2021) 1702. IF: 4.757, Q2
9. X. Yu# (并列一作), W. Li#, Q. Deng#, H. Liu, X. Wang, H. Hu, Y. Cao, Z.Y. Xu-Monette, L. Li, M. Zhang, Z Lu, K Young, Y Li*, MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis, Blood, 137 (2021) 1615-1627. IF: 25.476, Q1
10. L. Zhou#, X. Yu# (并列一作), M. Li#, G. Gong, W. Liu, T. Li, H. Zuo, W. Li*, F. Gao*, H. Liu*, Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth, EBioMedicine, 51 (2020) 102570. IF: 11.205, Q1
11. X. Yu# (并列一作), W. Li#, H. Liu, Q. Deng, X. Wang, H. Hu, Z.Y. Xu-Monette, W. Xiong, Z. Lu, K.H. Young, W Wang*, Y Li*, Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation, Journal of hematology & oncology, 13 (2020) 1-19. IF:29.5, Q1
12. W. Liu#, X. Yu# (并列一作), L. Zhou#, J. Li, M. Li, W. Li*, F. Gao*, Sinomenine inhibits non-small cell lung cancer via downregulation of hexokinases II-mediated aerobic glycolysis, OncoTargets and therapy, 13 (2020) 3209. IF: 4.345, Q2
13. M. Li#, F. Gao#, X. Yu# (并列一作), Q. Zhao, L. Zhou, W. Liu, W. Li*, Promotion of ubiquitination-dependent survivin destruction contributes to xanthohumol-mediated tumor suppression and overcomes radioresistance in human oral squamous cell carcinoma, Journal of Experimental & Clinical Cancer Research, 39 (2020) 1-15. IF: 12.658, Q1
14. F. Gao#, X. Yu# (并列一作), M. Li#, L. Zhou, W. Liu, W. Li, H. Liu, Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization, Cell death & disease, 11 (2020) 1-15. IF: 9.685, Q1
15. X. Yu# (并列一作), R. Wang#, Y. Zhang#, L. Zhou, W. Wang*, H. Liu*, W. Li*, Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin, Oncogene, 38 (2019) 7457-7472. IF: 8.756, Q1
